✦ LIBER ✦

Nuclear polymorphism in osteosarcomas as a prognostic factor for the effect of chemotherapy

✍ Scribed by Apel, R. ;Delling, G. ;Krumme, H. ;Winkler, K. ;Salzer-Kuntschik, M.

Publisher: Springer-Verlag
Year: 1985
Tongue: English
Weight: 577 KB
Volume: 405
Category: Article
ISSN: 0174-7398
DOI: 10.1007/bf00704373

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Age as a prognostic factor for patients

Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients

✍ Matthew T. Harting; Kevin P. Lally; Richard J. Andrassy; Ara A. Vaporciyan; Char 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 378 KB

Nuclear protein as a prognostic factor o

Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma

✍ Dohle, G. R. ;Beekhuis, J. A. M. ;van Steenbrugge, G. -J. ;Schröder, F. H. ;Tank 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 511 KB

Prognostic factors for osteosarcoma of t

Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy : 15-year experience in 789 patients treated at a single institution

✍ Gaetano Bacci; Alessandra Longhi; Michela Versari; Mario Mercuri; Antonio Bricco 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Evaluation of the prognostic factors in

Evaluation of the prognostic factors in gastric cancer: The effect of chemotherapy on survival

✍ Dr. D. Cunningham; D. Hole; D. J. Taggart; M. Soukop; D. C. Carter; C. S. McArdl 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

Platelet-derived growth factor receptor

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma

✍ Tadahiko Kubo; Sajida Piperdi; Jeremy Rosenblum; Cristina R. Antonescu; Wen Chen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 2 views

## Abstract The purpose of this review was to determine whether imatinib mesylate (STI571, Gleevec) has a role in the treatment of osteosarcoma. The expression of platelet‐derived growth factor (PDGF) receptor and its ligand was examined in a panel of surgical specimens obtained from 54 osteosarcom

Investigation of an NQO1 polymorphism as

Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia

✍ Asher Begleiter; Donna Hewitt; Spencer B. Gibson; James B. Johnston 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 395 KB

NAD(P)H:quinoneoxidoreductase 1 (NQO1) inhibits some cancers and increases p53 and apoptosis in cells. Due to an inactivating polymorphism, 10% of humans have no NQO1 activity. A case:control study suggested that chronic lymphocytic leukemia (CLL) patients may have an increased incidence of the NQO1